SAN DIEGO, March 24, 2017 /PRNewswire/ -- GenomeDx Biosciences today announced that six abstracts featuring Decipher GRID® (Genomics Resource Information Database) and Decipher® Prostate Cancer Classifier tests will be presented at the 32nd Annual European Association of Urology (EAU) Congress held March 24 to 28, 2017 in London, England. The Annual EAU Congress is Europe's largest urological event showcasing the latest and most comprehensive research in the urological field.
The abstract titled "Muscle invasive bladder cancer: A single sample patient assay to predict molecular subtypes and benefit of neoadjuvant chemotherapy" was chosen as the Best Abstract Oncology, and will be displayed at the e-Posters area (North Hall, Level 1) on Sunday, March 26, as well as during poster session 68.
In addition, the publication titled "Tissue-based Genomics Augments Post-Prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men," which features Decipher Post-Op, was selected as the Best Fundamental Research Paper Published in European Urology in 2016. Ashley Ross, M.D., Ph.D., the lead study author and associate professor of urology, Johns Hopkins Medical Center, will accept the award at the Award Gallery on Friday, March 24 at 4:15 p.m. GMT.
Poster Presentations
Title: The diverse genomic landscape of low-risk prostate cancer Date: Saturday, March 25 (2:15 p.m. to 3:45 p.m. GMT)Poster Number: 246Poster Session: 18Room: Stockholm, North Hall, Level 1Presenter: Matthew Cooperberg, M.D., M.P.H., University of California, San Francisco
Title: A genomic analysis of metastases-prone localized prostate cancer in a European high-risk populationDate: Sunday, March 26 (12:15 p.m. to 1:45 p.m. GMT)Poster Number: 483Poster Session: 36Room: Stockholm, North Hall, Level 1Presenter: Thomas Van den Broeck, M.D., University Hospitals Leuven
Title: Decipher test impacts decision-making among patients considering adjuvant and salvage treatment following radical prostatectomy: Interim results from the multicenter prospective PRO-IMPACT studyDate: Sunday, March 26 (12:15 p.m. to 1:45 p.m. GMT)Poster Number: 485Poster Session: 36Room: Stockholm, North Hall, Level 1Presenter: John L. Gore, M.D., M.S., University of Washington School of Medicine
Title: Transcriptome wide analysis of MRI-targeted biopsy and matching surgical specimens from high-risk prostate cancer patients treated with radical prostatectomyDate: Sunday, March 26 (12:15 p.m. to 1:45 p.m. GMT)Poster Number: 503Poster Session: 37Room: Munich, North Hall, Level 1Presenter: Boris Hadaschik, M.D., University of Heidelberg
Title: Her2 alterations in muscle-invasive bladder cancer: There is more than protein expression in patient selection for targeted therapyDate: Sunday, March 26 (2:00 p.m. to 3:30 p.m. GMT)Poster Number: 530Poster Session: 39Room: Madrid, North Hall, Level 1Presenter: Roland Seiler, M.D., University of British Columbia - Vancouver
Title: Muscle invasive bladder cancer: A single sample patient assay to predict molecular subtypes and benefit of neoadjuvant chemotherapyDate: Monday, March 27 (12:15 p.m. to 1:45 p.m. GMT)Poster Number: 901Poster Session: 68Room: Munich, North Hall, Level 1Presenter: Roland Seiler, M.D., University of British Columbia - Vancouver
About Decipher GRID® and Decipher® Prostate and Bladder Cancer Classifier Tests
GenomeDx's Decipher Genomics Resource Information Database (GRID) contains genomic profiles of thousands of tumors from patients with urological cancers, and is believed by GenomeDx to be the largest shared genomic expression database in urologic cancer as well as one of the world's largest global RNA expression databases using cloud-based analytics. GRID is a platform for interactive research collaboration, and may enable more rapid discovery, development, commercialization and adoption of new genomic solutions for key clinical questions in cancer treatment.
Derived from GRID, GenomeDx's Decipher Prostate and Bladder Cancer Classifier tests are commercially available genomic tests that provide a genomic assessment of tumor aggressiveness for individual patients. Decipher Biopsy is indicated for men with localized prostate cancer at diagnosis, Decipher Post-Op is indicated for men after prostate removal surgery and Decipher Bladder is indicated for patients being considered for neoadjuvant chemotherapy prior to radical cystectomy. The Decipher tests are used by physicians to stratify patients into more accurate risk groups than determined by traditional diagnostic tools and to better determine which patients may be more likely to benefit from additional treatment. Each tumor analyzed with a Decipher test adds new data points to the GRID database, which is compiled into a Decipher GRID Profile that may reveal additional biological characteristics of the tumor for ongoing research purposes. Going beyond risk stratification, Decipher and GRID makes accessible genetic information for researchers to potentially better predict responses to therapy and more precisely guide treatment.
More information is available at www.deciphertest.com and www.deciphergrid.com
About GenomeDx Biosciences
GenomeDx has reimagined the use of genomics as a platform for mass collaboration to improve treatment and outcomes of people with cancer. GenomeDx has built Decipher GRID, a large and fast-growing genomics database in urologic cancer that provides a foundation for open and interactive research collaboration and knowledge creation. Using Decipher GRID and machine learning to analyze vast amounts of genomic data, GenomeDx develops and commercializes proprietary clinical tests that are intended to provide more accurate and useful diagnostic information than traditional diagnostic tools or existing genomic tests. GenomeDx's Decipher Biopsy, Decipher Post-Op and Decipher Bladder are commercially available prostate cancer genomic tests that provide an assessment of tumor aggressiveness based on a patient's unique genomic profile. GenomeDx is headquartered in Vancouver, British Columbia and operates a clinical laboratory in San Diego, California.
Learn more at www.GenomeDx.com
Advertisement
The abstract titled "Muscle invasive bladder cancer: A single sample patient assay to predict molecular subtypes and benefit of neoadjuvant chemotherapy" was chosen as the Best Abstract Oncology, and will be displayed at the e-Posters area (North Hall, Level 1) on Sunday, March 26, as well as during poster session 68.
Advertisement
In addition, the publication titled "Tissue-based Genomics Augments Post-Prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men," which features Decipher Post-Op, was selected as the Best Fundamental Research Paper Published in European Urology in 2016. Ashley Ross, M.D., Ph.D., the lead study author and associate professor of urology, Johns Hopkins Medical Center, will accept the award at the Award Gallery on Friday, March 24 at 4:15 p.m. GMT.
Poster Presentations
Title: The diverse genomic landscape of low-risk prostate cancer Date: Saturday, March 25 (2:15 p.m. to 3:45 p.m. GMT)Poster Number: 246Poster Session: 18Room: Stockholm, North Hall, Level 1Presenter: Matthew Cooperberg, M.D., M.P.H., University of California, San Francisco
Title: A genomic analysis of metastases-prone localized prostate cancer in a European high-risk populationDate: Sunday, March 26 (12:15 p.m. to 1:45 p.m. GMT)Poster Number: 483Poster Session: 36Room: Stockholm, North Hall, Level 1Presenter: Thomas Van den Broeck, M.D., University Hospitals Leuven
Title: Decipher test impacts decision-making among patients considering adjuvant and salvage treatment following radical prostatectomy: Interim results from the multicenter prospective PRO-IMPACT studyDate: Sunday, March 26 (12:15 p.m. to 1:45 p.m. GMT)Poster Number: 485Poster Session: 36Room: Stockholm, North Hall, Level 1Presenter: John L. Gore, M.D., M.S., University of Washington School of Medicine
Title: Transcriptome wide analysis of MRI-targeted biopsy and matching surgical specimens from high-risk prostate cancer patients treated with radical prostatectomyDate: Sunday, March 26 (12:15 p.m. to 1:45 p.m. GMT)Poster Number: 503Poster Session: 37Room: Munich, North Hall, Level 1Presenter: Boris Hadaschik, M.D., University of Heidelberg
Title: Her2 alterations in muscle-invasive bladder cancer: There is more than protein expression in patient selection for targeted therapyDate: Sunday, March 26 (2:00 p.m. to 3:30 p.m. GMT)Poster Number: 530Poster Session: 39Room: Madrid, North Hall, Level 1Presenter: Roland Seiler, M.D., University of British Columbia - Vancouver
Title: Muscle invasive bladder cancer: A single sample patient assay to predict molecular subtypes and benefit of neoadjuvant chemotherapyDate: Monday, March 27 (12:15 p.m. to 1:45 p.m. GMT)Poster Number: 901Poster Session: 68Room: Munich, North Hall, Level 1Presenter: Roland Seiler, M.D., University of British Columbia - Vancouver
About Decipher GRID® and Decipher® Prostate and Bladder Cancer Classifier Tests
GenomeDx's Decipher Genomics Resource Information Database (GRID) contains genomic profiles of thousands of tumors from patients with urological cancers, and is believed by GenomeDx to be the largest shared genomic expression database in urologic cancer as well as one of the world's largest global RNA expression databases using cloud-based analytics. GRID is a platform for interactive research collaboration, and may enable more rapid discovery, development, commercialization and adoption of new genomic solutions for key clinical questions in cancer treatment.
Derived from GRID, GenomeDx's Decipher Prostate and Bladder Cancer Classifier tests are commercially available genomic tests that provide a genomic assessment of tumor aggressiveness for individual patients. Decipher Biopsy is indicated for men with localized prostate cancer at diagnosis, Decipher Post-Op is indicated for men after prostate removal surgery and Decipher Bladder is indicated for patients being considered for neoadjuvant chemotherapy prior to radical cystectomy. The Decipher tests are used by physicians to stratify patients into more accurate risk groups than determined by traditional diagnostic tools and to better determine which patients may be more likely to benefit from additional treatment. Each tumor analyzed with a Decipher test adds new data points to the GRID database, which is compiled into a Decipher GRID Profile that may reveal additional biological characteristics of the tumor for ongoing research purposes. Going beyond risk stratification, Decipher and GRID makes accessible genetic information for researchers to potentially better predict responses to therapy and more precisely guide treatment.
More information is available at www.deciphertest.com and www.deciphergrid.com
About GenomeDx Biosciences
GenomeDx has reimagined the use of genomics as a platform for mass collaboration to improve treatment and outcomes of people with cancer. GenomeDx has built Decipher GRID, a large and fast-growing genomics database in urologic cancer that provides a foundation for open and interactive research collaboration and knowledge creation. Using Decipher GRID and machine learning to analyze vast amounts of genomic data, GenomeDx develops and commercializes proprietary clinical tests that are intended to provide more accurate and useful diagnostic information than traditional diagnostic tools or existing genomic tests. GenomeDx's Decipher Biopsy, Decipher Post-Op and Decipher Bladder are commercially available prostate cancer genomic tests that provide an assessment of tumor aggressiveness based on a patient's unique genomic profile. GenomeDx is headquartered in Vancouver, British Columbia and operates a clinical laboratory in San Diego, California.
Learn more at www.GenomeDx.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/genomedxs-decipher-tests-and-decipher-grid-to-be-featured-in-multiple-presentations-at-the-32nd-annual-eau-congress-300428877.html
SOURCE GenomeDx Biosciences
